{"name":"Clexio Biosciences Ltd.","slug":"clexio-biosciences-ltd","ticker":"","exchange":"","domain":"clexio.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CLE-100","genericName":"CLE-100","slug":"cle-100","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"CLE-100","genericName":"CLE-100","slug":"cle-100","phase":"phase_2","mechanism":"CLE-100 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE9pS0R2QmtQR3MyZUVEV0daSVYzQ1paNFAyY1RGa2FWMk1xQ2ZyT1RKbFJ1bTBVSlN0UzVwTTZseUliRnFxTUp3ckh3RTRMcWRIQVhZTGpUQ1lvUWFvZGFUS1N6WWxqU1Nm?oc=5","date":"2025-12-21","type":"pipeline","source":"CTech","summary":"Syremis raises $165 million Series A to take on schizophrenia and other severe mental illnesses - CTech","headline":"Syremis raises $165 million Series A to take on schizophrenia and other severe mental illnesses","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNTGZyd3lZSHEyWDNNTnppOTUtY2s1UnNUTUlEakE2VjM1amttTktVaEpfR1ZaWFhqY1dublRleWh4WFFUOUVJRUttaDlkVjVsOVN2SnlGQTNKcVZfa3hGWEhOR2hWeThuTDlPOXhnMTBzUHY3Und1TWlERGN5N09mT210aTFGYzJ3SEJIZTc3OWtJOGVPRHRtWmJiNm5Nbl80eUJOS29qZXo?oc=5","date":"2025-12-21","type":"pipeline","source":"Globes - Israel Business News","summary":"Mental health treatment co Syremis Therapeutics raises $165m - Globes - Israel Business News","headline":"Mental health treatment co Syremis Therapeutics raises $165m - Globes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxNaVU3VGtzNlZlTHEwWFBoNEpqelptUlBFX28yN3FiaWNQWGRtU0wwZFY2MWs3bFlGbzZoUlpDTERvd1NucU9TeXQ5QzQwUlAtYkZGd1dmbTVSeS04UzFvenlkUlV0OXNxY0o3RHdxT3FZVzkyYXg1aVBST2s2NnJRWDl4ZmJSYUdMZ1JBWFZaaFBuX3JXMXUtbFhQbjdVUlhwdEJCRTBGdTVBdVBvUXhReUhTV2ktS2ZQTTZsb1ZXM0pFTXBQTVJxM282R3hWYWk5bjhvS0tBYzFWRHh0LUVSaThwZzdlcURlMTNuRDFRRXh5SjlHZkE?oc=5","date":"2025-12-18","type":"pipeline","source":"businesswire.com","summary":"Syremis Therapeutics Launches with $165M to Develop Best-in-Class Medicines for Mental Health Conditions - businesswire.com","headline":"Syremis Therapeutics Launches with $165M to Develop Best-in-Class Medicines for Mental Health Conditions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBMZXZqelJOT0trLVRsUWZrMWF3QkJtZEpneVVUdnJUVm9qN0hvTDYxX05qTFBQaHpncm5CY1FQa3NkQl9uODJMUENSQVMxeVpUS213?oc=5","date":"2025-12-18","type":"pipeline","source":"FirstWord Pharma","summary":"Neuropsych startup Syremis seeks to surpass muscarinic trail blazed by Cobenfy - FirstWord Pharma","headline":"Neuropsych startup Syremis seeks to surpass muscarinic trail blazed by Cobenfy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOTFEwWnU4SVhsTkhZM0tIMEl4aEdIY3FsVHdNV2xDcHczNnZWd3F4ckRzSlc0cWdXUnZTWmMxbVhvTFRpS1RyWGYtelpGOE1sOWpuVEhEUjQ2Rkx0cEtNVUZ0UnkwUVZLRzlDRmJhR1RHYlhoTDgxOVBtN1BXRzM3ZTR0bkQ5YVNnY2Q1N3hMdExJYmVhckZsYzEyVXlCcHlaekp1NC1md1RkRFZ0bERxZ3VCVDQ?oc=5","date":"2025-10-01","type":"regulatory","source":"Healio","summary":"FDA approves first oral therapy for chronic spontaneous urticaria - Healio","headline":"FDA approves first oral therapy for chronic spontaneous urticaria","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQX0NMTkpRanlRZFhWQjZFLXg5RjBxTUlRSnVrZkRBeUJXSkZKTUMxNG9xVEk0TWJ0Q0NSdVJDeFU1cE96WEJxVUI4N3J6M0x1NUNjZzZvdU41dTRQTG5IakFkMjhCdVFMYXNWU21UVFcwU3ZaSU5DVXU3NDBpU0c0c1pNR09raUMzaTQwalB4MnpaREJOcm9JZTMtTlhCNmJwWXNodk9wMWZEeXo0b3NyVzVZVEhxNDA?oc=5","date":"2025-07-02","type":"regulatory","source":"Healio","summary":"Psychedelics may improve psychotherapy outcomes, but obstacles remain - Healio","headline":"Psychedelics may improve psychotherapy outcomes, but obstacles remain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9TcWZTV1hpdU11dDdrNEN2MVpOejNUdU85cjlfbF9ad2hrUk41REhPanV3T0x3b05CR1pGYWFDcmd5SWNvVlJhWVBUNVF2cDd4eWY0ci1VbTVjelc2RnFv?oc=5","date":"2024-03-07","type":"trial","source":"Nature","summary":"Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial | Molecular Psychiatry - Natur","headline":"Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depre","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOVjdLT2xEVjFnbVlHMUwyZnBYWS1HemJXTDlEYk5UOF9kRXJCUVpmZjlnQl9UeHJ2c0o2eHRiTXV6eTQ5SkdqTDE4VkF5dThPOW9McXExR0RvblFNTVpOYXItMlZJTFpsTlNCZEVDbThHd0JwUVV1T0R3dV9Db2xaTlZqSm95aGo0RjRF?oc=5","date":"2023-08-14","type":"pipeline","source":"Psychiatrist.com","summary":"Have Effective Antidepressants Finally Arrived? Developments in Major Depressive Disorder Therapy - Psychiatrist.com","headline":"Have Effective Antidepressants Finally Arrived? Developments in Major Depressive Disorder Therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE92YmlKaTRMUDBpVkt6TU9KLVBIM3hjMTVZcUZiSnFpTkx6aV93LTNzYjVDYVVLYnNQZGUyTFh1LWctbGFEdG1ZQXF0MDNhM2FHNzhpVVZhaTRJZjI1dzFR?oc=5","date":"2022-02-01","type":"pipeline","source":"Nature","summary":"Edward F. Domino, Ph.D. (1924–2021) - Nature","headline":"Edward F. Domino, Ph.D. (1924–2021)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQbVNMZDJFVUtSSThhR1BaemFsalpXOG81SVp0WnZzWmlFZldBQlo5bUxVdmNGSVdqdGpMVzA1cmF6SjlyaGJnWGhjaVVNNjhpdHpUWXl3RGVyOHJOeDBYMmFDSms0SjVaVkVJZEsxaTZpVGtiUHZDd2NYNlNtUmlPcEd5b1dCMUg4VUxxbHFFd1F4dmc?oc=5","date":"2019-09-23","type":"pipeline","source":"The Times of Israel","summary":"Pharma exec Elisabeth Kogan shares her vision for Gvahim - The Times of Israel","headline":"Pharma exec Elisabeth Kogan shares her vision for Gvahim","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQeDhsZnl1RjlFQTJlbmRlbEk5aEUtS3gzVUozOThwYzNVcnItQXU1aUpld2VJTVRsZ21VN0xSTHBzQVJlZ1lTVndNUFFKU2RwNldCVzRKYnpsSEdjeUVoWEtSZF9Jc0FnczNkdEVFeS05dlhNeUNjalN6eHpDQmhRTWFzaDhXcmtSaTFJRFpNMHlOR29RV0F1N3lhVUtEQQ?oc=5","date":"2018-08-12","type":"pipeline","source":"Bloomberg.com","summary":"The Unlikely Source of a Healthtech Revolution - Bloomberg.com","headline":"The Unlikely Source of a Healthtech Revolution","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}